Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - MedImmune, Inc. (NasdaqNM:MEDI)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
35 West Watkins Mill Road
Gaithersburg, MD 20878
Phone: (301) 417-0770
Fax: (301) 527-4200
Email: ir@medimmune.com
Employees (last reported count): 790
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 500
 ·Nasdaq 100
Ownership
·Insider and 5%+ Owners: 22%
·Over the last 6 months:
 · 2 insider sells; 166.0K shares
  (0.4% of insider shares)
·Institutional: 73% (94% of float)
(952 institutions)
·Net Inst. Buying: 8.36M shares (+5.09%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
MedImmune, Inc. is a biotechnology company with five products on the market and a diverse portfolio of products in development. The Company is focused on using advances in immunology and other biological sciences to develop important new products that address significantly unmet medical needs in areas of infectious disease and immune regulation. The Company also focuses on oncology through its wholly owned subsidiary, MedImmune Oncology, Inc. The Company launched Synagis in the United States for preventing respiratory syncytial virus in high-risk pediatric patients. The Company also markets CytoGam and RespiGam, and has several product candidates undergoing clinical trials. Through MedImmune Oncology's sales and marketing group, the Company also markets Ethyol and NeuTrexin.
More from Market Guide: Expanded Business Description

Financial Summary
MEDI is focused on using advances in immunology and other biological sciences to develop important new products that address significant medical needs in areas such as infectious diseases, transplantation medicine, autoimmune diseases and cancer. For the six months ended 6/01, revenues rose 16% to $278.6 million. Net income before acct. change rose 22% to $69.4 million. Results reflect increased sales of Synagis and increased interest income due to higher cash balances.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Wayne Hockmeyer, Ph.D., 56
Chairman
$1.4M$33M
Melvin Booth, 56
Pres, COO, Director
988K47M
David Mott, 35
Vice Chairman, CEO
1.3M29M
Gregory Patrick, 49
CFO, Sr. VP
--  --  
James Young, Ph.D., 48
Pres, R&D
706K13M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:MEDIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$27.625
Recent Price$40.15 
52-Week High
on 25-Sep-2000
$86.125
Daily Volume (3-month avg)2.73M
Daily Volume (10-day avg)3.05M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-51.8%
52-Week Change
relative to S&P500
-35.3%
Share-Related Items
Market Capitalization$8.58B
Shares Outstanding213.7M
Float166.7M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.41 
Earnings (ttm)$0.70 
Earnings (mrq)-$0.04 
Sales (ttm)$2.61 
Cash (mrq)$2.31 
Valuation Ratios
Price/Book (mrq)9.10 
Price/Earnings (ttm)57.19 
Price/Sales (ttm)15.36 
Income Statements
Sales (ttm)$591.2M
EBITDA (ttm)$211.7M
Income available to common (ttm)$165.3M
Profitability
Profit Margin (ttm)28.0%
Operating Margin (ttm)35.4%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)17.06%
Return on Equity (ttm)19.50%
Financial Strength
Current Ratio (mrq)5.67 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$492.9M
Short Interest
As of 8-Aug-2001
Shares Short3.66M
Percent of Float2.2%
Shares Short
(Prior Month)
0 
Short Ratio1.40 
Daily Volume2.62M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.